Fundamental investigation of sustained and controlled therapeutics release from 3D printed medical devices
Source abstract
Abstract
Additive manufacturing has long been acclaimed as the tool for next-generation drug delivery device production. An ongoing challenge has remained with the best method of therapeutic incorporation into these devices as the layering mechanisms associated with 3D printing can be harsh and incompatible with most drugs of interest. We propose a method of post-fabrication absorption, or post-loading, of a silicone-based matrix fabricated with digital light synthesis (DLS). The fundamental mechanisms of this process were investigated using a simplified system of blocks with varied diffusion distances. We determined the critical role of specific surface area in the swelling, uptake, and in vitro release of two model drugs, β-estradiol (hydrophobic) and 2-fluoro-2′-deoxyadenosine (hydrophilic), and found sustained drug delivery to be driven by part geometry. The drug loading method was translated to a therapeutically relevant hydrophilic antiretroviral, 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA, Islatravir®), with sustained delivery over 70 days. Finally, we demonstrated the translation of this method into a medical device (intravaginal ring) using β-estradiol as a model drug. The gentle and efficient post-loading process enables the incorporation and sustained delivery of a range of drugs and opens the door for the exploration of long-term delivery of other active pharmaceutical ingredients (APIs).
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Additive Manufacturing and 3D Printing Technologies · 3D Printing in Biomedical Research · Nanofabrication and Lithography Techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (67)
Show source-provided references
1. Polymers for extended-release administration10.1007/s10544-019-0386-9 ↗
2. Polymers for drug delivery systems10.1146/annurev-chembioeng-073009-100847 ↗
3. Polymers in drug delivery-state of the art and future trends10.1002/adem.201080088 ↗
4. Long-acting injectable cabotegravir for the prevention of HIV infection10.1097/COH.0000000000000597 ↗
5. Sustained release drug delivery applications of polyurethanes10.3390/pharmaceutics10020055 ↗
6. Biodegradable polymers - a review10.4103/0250-474X.38465 ↗
7. Osmotic micropumps for drug delivery10.1016/j.addr.2012.02.003 ↗
8. Development, optimization and pharmacokinetic evaluation of biphasic extended-release osmotic drug delivery system of trospium chloride for promising application in treatment of overactive bladder10.1186/s43094-021-00311-6 ↗
9. Current strategies for sustaining drug release from electrospun nanofibers10.1016/j.jconrel.2015.09.008 ↗
10. Electrospun polymeric micro/nanofibrous scaffolds for long-term drug release and their biomedical applications10.1016/j.drudis.2017.05.007 ↗
11. A review of the effect of processing variables on the fabrication of electrospun nanofibers for drug delivery applications10.1155/2013/789289 ↗
12. Characterization of extracellular matrix modified poly(epsilon-caprolactone) electrospun scaffolds with differing fiber orientations for corneal stroma regeneration10.1016/j.msec.2019.110415 ↗
13. Tailoring surface nanoroughness of electrospun scaffolds for skeletal tissue engineering10.1016/j.actbio.2017.07.003 ↗
14. Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs10.1016/j.ijpharm.2021.120844 ↗
15. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery10.1038/s41467-019-12141-5 ↗
16. Drug release from in situ forming implants and advances in release testing10.1016/j.addr.2021.113912 ↗
17. Injectable hydrogels for sustained release of therapeutic agents10.1016/j.jconrel.2017.08.006 ↗
18. Solvent induced phase inversion-based in situ forming controlled release drug delivery implants10.1016/j.jconrel.2013.12.020 ↗
19. Effect of implant formation on drug release kinetics of in situ forming implants10.1016/j.ijpharm.2020.120105 ↗
20. In situ forming implants - an attractive formulation principle for parenteral depot formulations10.1016/j.jconrel.2012.04.016 ↗
21. Engineered hydrogels for local and sustained delivery of RNA-interference therapies10.1002/adhm.201601041 ↗
22. Combination therapy of killing Diseases by injectable hydrogels: from concept to medical applications10.1002/adhm.202001571 ↗
23. Chitosan hydrogels for sustained drug delivery10.1016/j.jconrel.2020.06.012 ↗
24. Injectable polymeric hydrogels for the delivery of therapeutic agents: a review10.1016/j.eurpolymj.2015.03.016 ↗
25. A review on recent advances in polymer and peptide hydrogels10.1039/C9SM02127B ↗
26. Drug-loaded hyaluronic acid hydrogel as a sustained-release regimen with dual effects in early intervention of tendinopathy10.1038/s41598-019-41410-y ↗
27. Channelled tablets: an innovative approach to accelerating drug release from 3D printed tablets10.1016/j.jconrel.2017.11.022 ↗
28. 3D inkjet printing of tablets exploiting bespoke complex geometries for controlled and tuneable drug release10.1016/j.jconrel.2017.06.025 ↗
29. Stereolithography (SLA) 3D printing of ascorbic acid loaded hydrogels: a controlled release study10.1016/j.ijpharm.2020.119428 ↗
30. Controlling release from 3D printed medical devices using CLIP and drug-loaded liquid resins10.1016/j.jconrel.2018.03.026 ↗
31. Modulating sustained drug release from nanocellulose hydrogel by adjusting the inner geometry of implantable capsules
32. Development of controlled release systems over the past 50years in the area of contraception10.1016/j.jconrel.2015.12.043 ↗
33. Standardization in additive manufacturing: activities carried out by international organizations and projects
34. A review of 3D printing technologies for soft polymer materials10.1002/adfm.202000187 ↗
35. Polymers for 3D printing and customized additive manufacturing10.1021/acs.chemrev.7b00074 ↗
36. 3D printing for drug delivery and biomedical applications10.1016/j.drudis.2020.07.007 ↗
37. Vat photopolymerization 3D printing for advanced drug delivery and medical device applications10.1016/j.jconrel.2020.10.008 ↗
38. A review of 3D printing Technology for medical applications10.1016/j.eng.2018.07.021 ↗
39. Hydrophilic excipients in digital light processing (DLP) printing of sustained release tablets: impact on internal structure and drug dissolution rate10.1016/j.ijpharm.2019.118790 ↗
40. Fused deposition modeling (FDM) 3D printed tablets for intragastric floating delivery of domperidone10.1038/s41598-017-03097-x ↗
41. 3D printing of drug-loaded gyroid lattices using selective laser sintering10.1016/j.ijpharm.2018.05.044 ↗
42. E-jet 3D-printed scaffolds as sustained multi-drug delivery vehicles in breast cancer therapy10.1007/s11095-019-2687-3 ↗
43. Role of build orientation in layered manufacturing: a review10.1504/IJMTM.2013.058637 ↗
44. Process–Structure–properties in polymer additive manufacturing via material extrusion: a review10.1080/10408436.2018.1549977 ↗
45. Part-scale build orientation optimization for minimizing residual stress and support volume for metal additive manufacturing: theory and experimental validation10.1016/j.cad.2019.03.004 ↗
46. The status, challenges, and future of additive manufacturing in engineering10.1016/j.cad.2015.04.001 ↗
47. Additive manufacturing: challenges, trends, and applications10.1177/1687814018822880 ↗
48. Fabrication of extended-release patient-tailored prednisolone tablets via fused deposition modelling (FDM) 3D printing10.1016/j.ejps.2014.11.009 ↗
49. Design, modeling and 3D printing of a personalized cervix tissue implant with protein release function10.1088/1748-605X/ab7b3b ↗
50. Continuous liquid interface production of 3D objects10.1126/science.aaa2397 ↗
51. Layerless fabrication with continuous liquid interface production10.1073/pnas.1605271113 ↗
52. Rethinking digital manufacturing with polymers10.1126/science.aaq1351 ↗
53. Xinyu Gu · 2018
54. Single-step fabrication of computationally designed microneedles by continuous liquid interface production10.1371/journal.pone.0162518 ↗
55. Design and characterization of a novel series of geometrically complex intravaginal rings with digital light synthesis10.1002/admt.202000261 ↗
56. Carbon3D · 2020
57. 4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-859110.1097/COH.0000000000000467 ↗
58. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms10.1074/jbc.M114.562694 ↗
59. Swelling of medical grade silicones in liquids and calculation of their cross-link densities10.1016/j.medengphy.2009.12.004 ↗
60. Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial10.1038/s41591-021-01479-3 ↗
61. Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV10.1111/cts.13048 ↗
62. Long-acting implants to treat and prevent HIV infection10.1097/COH.0000000000000591 ↗
63. Higuchi's equation and beyond: overview of the formulation and application of a generalized model of drug release from polymeric matrices10.1016/j.ijpharm.2012.08.012 ↗
64. Mechanisms of sustained action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices10.1002/jps.2600521210 ↗
65. Higuchi equation: derivation, applications, use and misuse10.1016/j.ijpharm.2011.03.051 ↗
66. Long-acting drugs and formulations for the treatment and prevention of HIV infection10.1016/j.ijantimicag.2020.106220 ↗
67. Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention10.1128/AAC.01058-18 ↗